August 2012
-
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Pharmaxis has adopted a positive opinion recommending the approval of a marketing authorization for Bronchitol inhaled dry powder mannitol formulation “for the treatment… Read more . . .
-
Over the past few months, the US Health and Human Service Department’s Agency for Healthcare Research and Quality (AHRQ) has issued several statistical briefs and a research finding regarding rising expenditures for asthma medications used… Read more . . .
-
Impel NeuroPharma has announced new funding for development of its Pressurized Olfactory Delivery (POD) device from a variety of sources. The company says that in addition to closing on over a half million dollars of… Read more . . .
-
Two experts in particle manufacturing for inhaled dry powder formulations, Hovione and Bend research, have entered into a non-exclusive collaboration in which they will have access to each other’s technologies. The partnership also gives Bend… Read more . . .
-
Insight Pharmaceuticals has voluntarily recalled a single lot of its Nostrilla oxymetazoline hydrochloride nasal spray due to possible contamination with Burkholderia cepacia bacteria. Nostrilla is available without prescription, and lot #11G075, which consisted of 34,092… Read more . . .
-
Hovione has launched a new service to provide proof of concept formulation for new dry powder formulations within a few weeks. The company says that its Rapid Proof of Concept Study will further simplify DPI… Read more . . .
-
SkyePharma has announced a delay in the review of the European Marketing Authorisation Application (“MAA”) for the Flutiform fluticasone propionate/formoterol fumarate metered dose inhaler (MDI) because the 21 Concerned Member States failed to reach consensus… Read more . . .
-
According to Perrigo, Alcon Labs has filed a patent infringement suit in the United States District Court for the Northern District of Texas after Perrigo filed an abbreviated new drug application (ANDA) for a generic… Read more . . .
-
Novartis; Basel, Switzerland Engineer I and Fellow/Engineer II Engineer I Job ID number 85034BR Design, plan, perform, interpret and report results of studies related to development and related processes and procedures of medical devices including… Read more . . .
-
Inhalation scientists Hyderabad, India Necessary Background & Experience: • Experience with method development, validation for inhalation dosage forms (DPI, MDIs) • Experience with specialized analytical instruments such as Anderson cascade impactor (ACI), next generation impactor… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland